T54 inhibitors are a class of small molecules known for their ability to selectively bind and inhibit the activity of certain enzymes or proteins within biological systems. These inhibitors are typically characterized by their specificity toward a target protein or enzyme involved in critical cellular processes, which can include signal transduction pathways, metabolic regulation, or protein synthesis. Structurally, T54 inhibitors are often designed through rational drug design approaches, which involve understanding the three-dimensional configuration of the target protein's active site. By leveraging computational tools such as molecular docking and high-throughput screening, researchers can identify molecular scaffolds that effectively interact with key amino acid residues of the protein, forming stable complexes that block the enzymatic activity. This mechanism can lead to alterations in the protein's function, which may result in downstream changes in cellular physiology or the inhibition of specific biochemical pathways.
The chemical structure of T54 inhibitors often includes a variety of functional groups that facilitate strong non-covalent interactions, such as hydrogen bonding, hydrophobic contacts, and van der Waals forces. These interactions enhance the binding affinity of the inhibitor to its target. In some cases, the inhibitors can also incorporate metal-binding groups, which chelate essential metal ions in metalloenzymes, further impeding enzymatic activity. Importantly, the design of T54 inhibitors requires careful consideration of the molecular geometry to ensure high selectivity, minimizing off-target effects and undesirable interactions with other biomolecules. Their design can also involve optimizing pharmacokinetic properties like solubility and stability, although these factors are generally secondary to their primary function of enzyme inhibition in biochemical research. Through detailed structural analysis, T54 inhibitors can serve as useful tools in elucidating the role of specific proteins in various cellular processes.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine could decrease T54 mRNA levels by inhibiting various protein kinases that promote the transcription of T54 through activation of specific transcription factors or signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may reduce T54 protein synthesis by targeting the mTOR signaling pathway, which is crucial for cell growth and translation control, potentially including proteins encoded by the T54 gene. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may decrease T54 expression by inducing hypomethylation of the gene's promoter region, leading to a closed chromatin configuration less conducive to transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D may inhibit T54 expression by intercalating into DNA, preventing the advancement of RNA polymerase during transcription of the T54 gene. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide could decrease T54 protein levels by blocking the translocation step in protein synthesis, thereby halting the translation of T54 mRNA. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A might reduce T54 expression by inhibiting histone deacetylase, leading to hyperacetylation of histones and altered gene expression patterns of genes including T54. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could downregulate T54 expression by inhibiting PI3K, thereby suppressing the downstream AKT signaling pathway, which may be necessary for T54 gene expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 may lead to decreased levels of T54 by selectively inhibiting MEK1/2, which are part of the MAPK/ERK pathway, a pathway that often controls the expression of various genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 may lead to reduced expression of T54 by inhibiting MEK, thereby disrupting the MAPK/ERK pathway and potentially altering transcription factor activity necessary for T54 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 could inhibit T54 expression by targeting p38 MAPK, which may play a role in the cellular stress response that includes the regulation of gene expression. |